NASDAQ:MPLT Maplight Therapeutics (MPLT) Stock Price, News & Analysis $6.52 -0.38 (-5.46%) As of 10:58 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Maplight Therapeutics Stock (NASDAQ:MPLT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Maplight Therapeutics alerts:Sign Up Key Stats Today's Range$6.56▼$6.9350-Day Range$6.22▼$13.9552-Week Range$6.06▼$40.43Volume54,900 shsAverage Volume458,682 shsMarket Capitalization$362.55 millionP/E RatioN/ADividend YieldN/APrice Target$29.50Consensus RatingModerate Buy Company Overview MapLight Therapeutics is a clinical-stage biopharmaceutical company developing medicines for people with serious brain disorders. Its research focuses on treatments intended to address symptoms that can be difficult to manage with existing therapies. The company’s investigational programs include ML-007 for schizophrenia and ML-004 for autism spectrum disorder. These candidates remain in development and are not approved medicines.AI Generated. May Contain Errors. Read More Maplight Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreMPLT MarketRank™: 3.24112248969 of 5 starsMaplight Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 304th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingMaplight Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 4 strong buy ratings, 9 buy ratings, 4 hold ratings, and 1 sell rating.Upside PotentialMaplight Therapeutics has a consensus price target of $29.50, representing about 327.5% upside from its current price of $6.90.Amount of Analyst CoverageMaplight Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Maplight Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Maplight Therapeutics are expected to grow in the coming year, from ($5.01) to ($4.12) per share.Price to Book Value per Share RatioMaplight Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.08% of the float of Maplight Therapeutics has been sold short.Short Interest Ratio / Days to CoverMaplight Therapeutics has a short interest ratio ("days to cover") of 10.31, which indicates bearish sentiment.Change versus previous monthShort interest in Maplight Therapeutics has recently decreased by 2.14%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaplight Therapeutics does not currently pay a dividend.Dividend GrowthMaplight Therapeutics does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.21 News SentimentMaplight Therapeutics has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Maplight Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for MPLT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Maplight Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Maplight Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $990,690.00 in company stock.Percentage Held by Insiders3.80% of the stock of Maplight Therapeutics is held by insiders.Percentage Held by InstitutionsMaplight Therapeutics has minimal institutional ownership at this time.Read more about Maplight Therapeutics' insider trading history. Receive MPLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maplight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MPLT Stock News HeadlinesMapLight Moves Toward Phase 3 Schizophrenia Trial; VISTA Study Enrollment ContinuesNovember 16 at 6:28 PM | rttnews.comMapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNovember 16 at 7:15 AM | globenewswire.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 17 at 1:00 AM | Behind the Markets (Ad)MapLight Therapeutics to Participate in Upcoming Investor ConferenceNovember 9, 2026 | globenewswire.comMapLight: 'Hold' Rating On ML-007C-MA In Schizophrenia And 2nd Half 2027 ADP Data ReadoutOctober 28, 2026 | seekingalpha.comInsider Selling: Maplight Therapeutics (NASDAQ:MPLT) CFO Sells 10,167 Shares of StockOctober 17, 2026 | insidertrades.comMapLight co-founder is joint winner of 2026 Nobel Prize in MedicineOctober 6, 2026 | seekingalpha.comMapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of OptogeneticsOctober 6, 2026 | globenewswire.comSee More Headlines MPLT Stock Analysis - Frequently Asked Questions How have MPLT shares performed this year? Maplight Therapeutics' stock was trading at $17.57 at the beginning of the year. Since then, MPLT shares have decreased by 60.7% and is now trading at $6.90. How were Maplight Therapeutics' earnings last quarter? Maplight Therapeutics, Inc. (NASDAQ:MPLT) released its quarterly earnings results on Monday, November, 16th. The company reported ($0.97) earnings per share for the quarter, beating analysts' consensus estimates of ($1.22) by $0.25. When did Maplight Therapeutics IPO? Maplight Therapeutics (MPLT) raised $252 million in an initial public offering (IPO) on the week of October 27th 2025. The company issued 14,800,000 shares at $17.00 per share. Morgan Stanley, Jefferies, Leerink and Stifel acted as the underwriters for the IPO. Who are Maplight Therapeutics' major shareholders? Maplight Therapeutics' top institutional investors include Goldman Sachs Group Inc. (6.48%), Baker BROS. Advisors LP (2.10%), Marshall Wace LLP (1.10%) and Blue Owl Capital Holdings LP (1.00%). Insiders that own company stock include Christopher A Kroeger, Vishwas Setia, Robert C Malenka, Erin Pennock Foff, James Woodruff Lillie, Anatol Kreitzer, Jonathan Gillis, George Pavlov, Troy Cox and Timothy John Garnett. View institutional ownership trends. How do I buy shares of Maplight Therapeutics? Shares of MPLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/16/2026Today11/17/2026Jefferies Global Healthcare Conference11/18/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:MPLT CIK1770069 Webmaplightrx.com Phone(650) 839-4360FaxN/AEmployees133Year Founded2018Price Target and Rating Average Price Target for Maplight Therapeutics$29.50 High Price Target$46.00 Low Price Target$13.00 Potential Upside/Downside+351.8%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($42.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$161.15 million Net MarginsN/A Pretax MarginN/A Return on Equity-98.60% Return on Assets-60.33% Debt Debt-to-Equity RatioN/A Current Ratio16.52 Quick Ratio16.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.10 per share Price / Book0.65Miscellaneous Outstanding Shares55,580,000Free Float53,464,000Market Cap$362.94 million OptionableOptionable BetaN/A 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:MPLT) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maplight Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maplight Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.